Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 391-397

  Broedl, Uli C ^a   Schachinger, Veronika ^a   Lingenhel, Arno ^b   Lehrke, Michael ^a   Stark, Renee ^c   Seibold, Frank ^d   Göke, Burkhard ^a   Kronenberg, Florian ^b   Parhofer, Klaus G ^a   Konrad Zerna, Astrid ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

apoA IV; Crohn's disease; Disease activity; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

APOLIPOPROTEIN A4; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DNA POLYMORPHISM; ENTERITIS; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS A; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENETIC MARKERS; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; RECURRENCE;

EID: 34247636566     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20078     Document Type: Article

References (44)

1. Green PH, Glickman RM, Riley JW, et al. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest. 1980;65:911-919.
2. Ghiselli G, Krishnan S, Beigel Y, et al. Plasma metabolism of apolipoprotein A-IV in humans. J Lipid Res. 1986;27:813-827.
3. Lefevre M, Roheim PS. Metabolism of apolipoprotein A-IV. J Lipid Res. 1984;25:1603-1610.
4. Ezeh B, Haiman M, Alber HF, et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res. 2003;44:1523-1529.
5. Apfelbaum TF, Davidson NO, Glickman RM. Apolipoprotein A-IV synthesis in rat intestine: regulation by dietary triglyceride. Am J Physiol. 1987;252:G662-666.
6. Fujimoto K, Cardelli JA, Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol. 1992;262:G1002-1006.
7. Aalto-Setala K, Bisgaier CL, Ho A, et al. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior. J Clin Invest. 1994;93:1776-1786.
8. Weinstock PH, Bisgaier CL, Hayek T, et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res. 1997;38:1782-1794.
9. Steinmetz A, Barbaras R, Ghalim N, et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells.J Biol Chem. 1990;265:7859-7863.
10. Chen CH, Albers JJ. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. Biochim Biophys Acta. 1985;836:279-885.
11. Steinmetz A, Utermann G. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem. 1985;260:2258-2264.
12. Stein O, Stein Y, Lefevre M, et al. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta. 1986;878:7-13.
13. Dvorin E, Gorder NL, Benson DM, et al. Apolipoprotein A-IV. A determinant for binding and uptake of high density lipoproteins by rat hepatocytes. J Biol Chem. 1986;261:15714-15718.
14. Goldberg IJ, Scheraldi CA, Yacoub LK, et al. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem. 1990;265:4266-4272.
15. Emmanuel F, Steinmetz A, Rosseneu M, et al. Identification of specific amphipathic alpha-helical sequence of human apolipoprotein A-IV involved in lecithin:cholesterol acyltransferase activation. J Biol Chem. 1994;269:29883-29890.
16. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. J Lipid Res. 1994;35:982-992.
17. Main LA, Ohnishi T, Yokoyama S. Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. Biochim Biophys Acta. 1996;1300:17-24.
18. Qin X, Swertfeger DK, Zheng S, et al. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol. 1998;274: H1836-1840.
19. Ostos MA, Conconi M, Vergnes L, et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1023-1028.
20. Duverger N, Tremp G, Caillaud JM, et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996; 273:966-968.
21. Cohen RD, Castellani LW, Qiao JH, et al. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 1997;99:1906-1916.
22. Kronenberg F, Stuhlinger M, Trenkwalder E, et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol. 2000;36:751-757.
23. Wong WM, Hawe E, Li LK, et al.Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92:969-975.
24. Warner MM, Guo J, Zhao Y. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl). 2001;114:275-279.
25. Jansen S, Lopez-Miranda J, Salas J, et al. Effect of 347-serine mutation in apoprotein A-IV on plasma LDL cholesterol response to dietary fat. Arterioscler Thromb Vasc Biol. 1997;17:1532-1538.
26. Jansen S, Lopez-Miranda J, Ordovas JM, et al. Effect of 360His mutation in apolipoprotein A-IV on plasma HDL-cholesterol response to dietary fat. J Lipid Res. 1997;38:1995-2002.
27. Weinberg RB, Jordan MK, Steinmetz A. Distinctive structure and function of human apolipoprotein variant ApoA-IV-2. J Biol Chem. 1990; 265:18372-18378.
28. Rader DJ, Schafer J, Lohse P, et al. Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein. J Clin Invest. 1993;92:1009-1017.
29. Rewers M, Kamboh MI, Hoag S, et al. ApoA-IV polymorphism associated with myocardial infarction in obese NIDDM patients. The San Luis Valley Diabetes Study. Diabetes. 1994;43:1485-1489.
30. Campos H, Lopez-Miranda J, Rodriguez C, et al. Urbanization elicits a more atherogenic lipoprotein profile in carriers of the apolipoprotein A-IV-2 allele than in A-IV-1 homozygotes. Arterioscler Thromb Vasc Biol. 1997;17:1074-1081.
31. Kretowski A, Hokanson JE, McFann K, et al. The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes. Diabetologia. 2006;49:1946-1954.
32. Vowinkel T, Mori M, Krieglstein CF, et al. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest. 2004;114:260-269.
33. Spaulding HL, Saijo F, Turnage RH, et al. Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competent, undifferentiated cells by modulating intracellular glutathione redox balance. Am J Physiol Cell Physiol. 2006;290:C95-C103.
34. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
35. Fisher RM, Burke H, Nicaud V, et al. Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. EARS Group. J Lipid Res. 1999;40:287-294.
36. Kronenberg F, Kuen E, Ritz E, et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol. 2002;13:461-469.
37. Haiman M, Salvenmoser W, Scheiber K, et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int. 2005;68:1130-1136.
38. Kronenberg F, Lobentanz EM, Konig P, et al. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res. 1994;35:1318-1328.
39. Dieplinger H, Lobentanz EM, Konig P, et al. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest. 1992;22:166-174.
40. Lingenhel A, Eder C, Zwiauer K, et al. Decrease of plasma apolipoprotein A-IV during weight reduction in obese adolescents on a low fat diet. Int J Obes Relat Metab Disord. 2004;28:1509-1513.
41. Schurmann GM, Bishop AE, Facer P, et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut. 1995;36:411-418.
42. Gironella M, Molla M, Salas A, et al. The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice. J Leukoc Biol. 2002;72:56-64.
43. Wan MX, Riaz AA, Schramm R, et al. Leukocyte rolling is exclusively mediated by P-selectinin colonic venules. Br J Pharmacol. 2002;135: 1749-1756.
44. Kim M, Lee S, Yang SK, et al. Differential expression in histologically normal crypts of ulcerative colitis suggests primary crypt disorder. Oncol Rep. 2006;16:663-670.